3.77  -0.09 (-2.33%)		10-30 16:00
Open: 3.74 High: 3.885 Volume: 117,787		Pre. Close: 3.86 Low: 3.695 Market Cap: 24(M)

Short term
Mid term
Targets	6-month :	5.55	1-year :	6.43
Resists	First :	4.75	Second :	5.51
Pivot price	3.83
Supports	First :	3.53	Second :	2.94
MAs	MA(5) :	3.83	MA(20) :	4.02
	MA(100) :	4.49	MA(250) :	5.44
MACD	MACD :	-0.3	Signal :	-0.3
%K %D	K(14,3) :	39.7	D(3) :	31.6
RSI	RSI(14): 37.8
52-week	High :	9.11	Low :	3.52

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ SCYX ] has closed above bottom band by 33.6%. Bollinger Bands are 70.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.89 - 3.91	3.91 - 3.93
Low:	3.64 - 3.67	3.67 - 3.69
Close:	3.73 - 3.77	3.77 - 3.81

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Thu, 29 Oct 2026
A live webcast will feature SCYNEXIS leaders on Nov. 9 - Stock Titan

Thu, 22 Oct 2026
56 healthy participants had no drug-related serious events with an experimental antifungal. - Stock Titan

Thu, 22 Oct 2026
SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street

Tue, 22 Sep 2026
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan

Sat, 25 Jul 2026
SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView

Thu, 25 Jun 2026
SCYX Forecast — Price Target — Prediction for 2027 - TradingView

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Shares Out	0 (M)
Shares Float	10 (M)
Held by Insiders	7.35e+006 (%)
Held by Institutions	2 (%)
Shares Short	454 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	-53.3 %
Operating Margin	-3 %
Return on Assets (ttm)	308.5 %
Return on Equity (ttm)	-20.9 %
Qtrly Rev. Growth	1.922e+007 %
Gross Profit (p.s.)	-78.12
Sales Per Share	-17.34
EBITDA (p.s.)	1.81321e+007
Qtrly Earnings Growth	-0.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-13 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	-0.22
Price to Cash Flow	0.59

Dividend	0
Forward Dividend	594320
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.